Table 3. Comparison of the two major randomised controlled trials of CPAP for OSA in CHF due to left ventricular systolic failure.
| Comparison items | Kaneko (13) | Mansfield (12) |
|---|---|---|
| Patient number (completed/enrolled) | 24/138 | 55/156 |
| Drop-outs | Not stated | 15/55 |
| Study duration (months) | 1 | 3 |
| Threshold | ||
| OSA/OSA & CSA (%) | >50 | >80 |
| AHI (eph) | >20 | >5 |
| LVEF (%) | <45 | <55 |
| CPAP (mean pressure × nightly use) | 8.9×6.2 | 8.8×5.6 |
| Outcomes | ||
| Change in LVEF (%) | 27-36 | 35-40 |
| Left ventricular dimensions | Reduced | Not measured |
| Quality of life | Not measured | Improved |
| Blood pressure | Reduced | No change |
| Urinary norepinephrine | No measured | Reduced |
PAP, continuous positive airway pressure; OSA, obstructive sleep apnea; CSA, central sleep apnea; AHI, apnea hypopnea index; LVEF, left ventricular ejection fraction.